Avalo Therapeutics, Inc. current report, 14 March 2017

Business Context and Reporting Period

This Form 8-K is a current report filed by Cerecor Inc. on March 14, 2017. The filing serves to announce the company's financial results for the fourth quarter and the full fiscal year ended December 31, 2016. The detailed results are contained in a press release furnished as Exhibit 99.1.

Key Financial Metrics

The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this 8-K document.

Material Changes

The filing does not provide specific data regarding material changes versus prior periods. It solely references the issuance of the press release containing the comparative financial results.

Guidance, Outlook, and Risks

The text does not include specific guidance, outlook, management commentary, or risk factors. It notes that the information in Item 2.02 and Exhibit 99.1 is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it subject to the liabilities of that section.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release dated March 14, 2017) for actual financial figures.
  • Verify the specific revenue and net loss figures for Q4 and FY 2016 in the press release.
  • Check the press release for cash position and burn rate details not included in this summary.
  • Confirm any updates on clinical trial progress or pipeline milestones mentioned in the full press release.